Efficacy of Upadacitinib in Resolving Refractory Oral Lichen Planus A Case Study

Files

Authors

Alyssa P. Quinn
Trevor Nessel, Beaumont Health Resident
Francisca Kartono, Beaumont Health

Description

Lichen planus (LP) is an autoimmune disorder mediated by T-cells, where inflammatory cells target an unidentified protein in the skin and mucosal keratinocytes.

LP affects 1 in 100 individuals globally, primarily adults over the age of forty.

About 50% of LP patients develop oral lesions, occurring more often in women compared to men.

Cutaneous LP often clears within a few years while mucosal LP can persist for more than a decade.

Genetic predisposition, stress, tissue injury, contact allergy, and drug reactions are risk factors.

Common treatment options: Topical and intralesional corticosteroids, topical immunosuppressants (tacrolimus and pimecrolimus).

There is some evidence supporting the efficacy of upadacitinib in achieving rapid resolution of oral LP.

Publication Date

5-5-2023

Disciplines

Dermatology

Recommended Citation

Quinn A, Nessel T, Kartono F . Efficacy of upadacitinib in resolving refractory oral lichen planus a case study. Presented at Beaumont Hospital Farmington Hills 2023 Alvin Yarrows Research Day; 2023 May 4; Farmington Hills, MI.

Comments

2023 Alvin Yarrows Research Day at Beaumont Hospital Farmington Hills, Farmington Hills, MI, May 4, 2023.